RUA — Rua Bioscience Share Price
- NZ$10.75m
- NZ$8.42m
- NZ$0.36m
- 34
- 17
- 22
- 13
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.13 | ||
Price to Tang. Book | 1.48 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 34.48 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -184.4% | ||
Return on Equity | -96.94% | ||
Operating Margin | -5676.46% |
Financial Summary
Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | NZ$m | n/a | n/a | n/a | 0.02 | 0.36 | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Rua Bioscience Limited is a New Zealand-based medicinal cannabis company. The Company is engaged in the business of research and development, and pharmaceutical distribution and marketing. The Company is focused on breeding, cultivating, manufacturing, and supplying medicinal cannabis. The Company operates through one segment: research and development and the sale of pharmaceutical products in Germany and New Zealand. The Company also operates a full research laboratory in Gisborne, which enables cannabinoid testing, microscopic analysis, moisture analysis, sample preparation and extraction, solvent removal, viscosity measurements, and impurity testing.
Directors
- Trevor Burt CHM (63)
- Rob Mitchell CEO
- Hamish White CFO
- Manu Caddie OTH
- Andrea Grant OTH
- Panapa Ehau DRC
- Brett Gamble DRC
- Martin Smith DRC
- Anna Stove IND
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- October 26th, 2017
- Public Since
- October 22nd, 2020
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- New Zealand Stock Exchange
- Shares in Issue
- 158,136,265
- Address
- 1 Commerce Place, Awapuni, GISBORNE, 4071
- Web
- https://www.ruabio.com/
- Phone
- +64 63906938
- Auditors
- PricewaterhouseCoopers Chartered Accountants
Upcoming Events for RUA
Rua Bioscience Ltd Annual Shareholders Meeting
Similar to RUA
AFT Pharmaceuticals
New Zealand Stock Exchange
BLIS Technologies
New Zealand Stock Exchange
EBOS
New Zealand Stock Exchange
FAQ
As of Today at 19:18 UTC, shares in Rua Bioscience are trading at NZ$0.07. This share price information is delayed by 15 minutes.
Shares in Rua Bioscience last closed at NZ$0.07 and the price had moved by -60.47% over the past 365 days. In terms of relative price strength the Rua Bioscience share price has underperformed the ASX All Ordinaries Index by -62.18% over the past year.
There is no consensus recommendation for this security.
Rua Bioscience does not currently pay a dividend.
Rua Bioscience does not currently pay a dividend.
Rua Bioscience does not currently pay a dividend.
To buy shares in Rua Bioscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of NZ$0.07, shares in Rua Bioscience had a market capitalisation of NZ$10.75m.
Here are the trading details for Rua Bioscience:
- Country of listing: New Zealand
- Exchange: NZC
- Ticker Symbol: RUA
Based on an overall assessment of its quality, value and momentum Rua Bioscience is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Rua Bioscience. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -42.36%.
As of the last closing price of NZ$0.07, shares in Rua Bioscience were trading -39.6% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Rua Bioscience PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at NZ$0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Rua Bioscience's management team is headed by:
- Trevor Burt - CHM
- Rob Mitchell - CEO
- Hamish White - CFO
- Manu Caddie - OTH
- Andrea Grant - OTH
- Panapa Ehau - DRC
- Brett Gamble - DRC
- Martin Smith - DRC
- Anna Stove - IND